SUVEN PHARMACEUTICALS : Q4 2024 Financial Quarterly Report : YoY Sales Down 31.52 %, QoQ Up 15.06 %

The comprehensive analytics outlining the performance and outlook of SUVEN PHARMACEUTICALS LIMITED”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at SUVEN PHARMACEUTICALS LIMITED’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -31.52 %. However, it did see a marginal increase of 15.06 % from the previous quarter. Expenses ticked up slightly by 16.11 % quarter-on-quarter, aligning with the annual decline of -10.33 %. Operating profit, while down -56.62 % compared to last year, faced a quarter-on-quarter increase of 12.57 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -16.78 %, but a shrinkage of -0.64 % sequentially. Other income rose by 18.9 % compared to the last quarter, despite an annual growth of 49.56 %. Interest expenses surged remarkably by 81.1 % from the previous quarter, yet the year-over-year decrease remains at a moderate -0.43 %. Depreciation costs climbed by 35.29 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 44.23 %. Profit before tax declined annually by -57.38 % but saw an increase from the preceding quarter by 8.2 %.
Tax expenses as a percentage of profits decreased slightly by -0.74 % compared to last year, with a more notable quarter-on-quarter decrease of -3.92 %. Net profit fell by -56.95 % year-on-year but experienced a 14.16 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -56.88 % but a quarterly rise of 14.13 %. In summary, SUVEN PHARMACEUTICALS LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing SUVEN PHARMACEUTICALS LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -31.52 % year-on-year, however, there was a minor increase of 15.06 % from the previous quarter. Expenses decreased by -10.33 % compared to the previous year, with a 16.11 % increase quarter-on-quarter. Operating Profit dropped by -56.62 % annually, and saw a 12.57 % increase from the last quarter.
Net Profit showed yearly decrease of -56.95 %, and experienced a 14.16 % increase from the previous quarter. Earnings Per Share (EPS) fell by -56.88 % annually, however rose by 14.13 % compared to the last quarter. In essence, while SUVEN PHARMACEUTICALS LIMITED faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.